The parallel review proposal calls for establishing a process for overlapping evaluations of such medical devices when the product sponsor and both agencies agree to such parallel review.
CMS and FDA believe this process will serve the public interest by reducing the time between FDA marketing approval or clearance decisions and CMS national coverage determinations (NCDs).
According to the news release, MDMA’s concerns focused on:
• how the proposal might be harmful to innovative medical device companies by forcing them to participate;
• the importance of reimbursement coding reform in order to minimize the delays between the regulatory and reimbursement process;
• an alternative to NCDs to ensure they are not the only pathway to coverage; and
• the need for strong protections for a company’s proprietary data.
Read the MDMA news release about its concerning regarding parallel review.
Read more about medical devices:
– Prevailing in Vendor Contract Negotiations: 5 Best Practices
– Medical Device Group Lobbies Congress on Patient Lawsuits, FDA Approval System
– William Blair & Co.: 2011 Orthopedic and Spine Device Market Will Be Difficult But Better Than 2010
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
